- Arbutus Biopharma ABUS-2.56% secured $2.25B via a Moderna MRNA+0.26% patent settlement, using $230M to repurchase 23% of shares at $5.00. - Post-buyback, the stock fell to $4.12 as settlement cash ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results